# Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants

> **NCT01487512** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 29 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Treatment A: Hydromorphone 8 mg
- **DRUG:** Treatment B: Hydromorphone 16 mg
- **DRUG:** Treatment C: Hydromorphone 32 mg
- **DRUG:** Treatment D: Hydromorphone 64 mg

## Key facts

- **NCT ID:** NCT01487512
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2012-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487512, "Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01487512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*